Notwithstanding the advancement of several small molecule inhibitors aimed at the PI3K/AKT/mTOR pathway [18, 19], the upstream regulators and molecular mechanisms driving the aberrant PI3K/AKT/mTOR pathway in AML remain incompletely understood. Here, MTOR is linked to acute myeloid leukemia.